Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$689,000.

  • Centessa Pharmaceuticals' Change in Accured Expenses rose 82.02% to -$689,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 167.89%. This contributed to the annual value of $22.8 million for FY2024, which is 2957.09% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Change in Accured Expenses of -$689,000 as of Q3 2025, which was down 123.92% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Change in Accured Expenses registered a high of $32.7 million during Q4 2024, and its lowest value of -$29.6 million during Q1 2025.
  • Its 3-year average for Change in Accured Expenses is -$489,455, with a median of $147,000 in 2023.
  • Over the last 5 years, Centessa Pharmaceuticals' Change in Accured Expenses had its largest YoY gain of 1,501.47% in 2024, and its largest YoY loss of 2,706.12% in 2024.
  • Centessa Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at -$4.8 million in 2022, then spiked by 142.28% to $2.0 million in 2023, then spiked by 1,501.47% to $32.7 million in 2024, then surged by 82.02% to -$689,000 in 2025.
  • Its Change in Accured Expenses stands at -$689,000 for Q3 2025, versus $2.9 million for Q2 2025 and -$29.6 million for Q1 2025.